Kornimate/medical-research-clean huggingface dataset:
validation of the thai version cpot and bps in postoperative icu patients

Conditions: Adult ICU Patients

Summary: the prospective study set forth to test thai version cpot and bps for validity, reliability, and practicality. after translation, both pain scales were tested for concurrent validity, discriminant validity, criterion validity, and inter-rater reliability in patients who were intubated during the postoperative period. opinions regarding practicality were elicited via questionnaires from nurses who had been using and were familiar with these two pain scales.

the prospective study set forth to test thai version cpot and bps for validity, reliability, and practicality. after translation, both pain scales were tested for concurrent validity, discriminant validity, criterion validity, and inter-rater reliability in patients who were intubated during the postoperative period. opinions regarding practicality were elicited via questionnaires from nurses who had been using and were familiar with these two pain scales.

Eligibility criteria:
inclusion criteria: * aged ≥18 years * be able to communicate in thai * intubated during postoperative period. exclusion criteria: * quadriplegia * patients with limb or facial injuries * patients receiving neuromuscular blockers * patients with limb mobility adversely affected by stroke * patients with epidural catheter used for postoperative pain control

Keywords: thai version validated critical care pain observation tool behavioral pain scale adult icu patients
effect of transcutaneous auricular vagus nerve stimulation on gait characteristics in parkinson's disease

Conditions: Parkinson Disease; Gait Disorders, Neurologic

Summary: in this randomised placebo-controlled trial, the investigators will include 30 pd (parkinson's disease) patients with hy (hoehn yahr stage) \>2 and l-dopa unresponsive gait characteristics. each participant will receive tavns at 25hz, tavns at 100hz and sham vns (svns). during each stimulation, different gait characteristics will be measured with wearable insertion motion sensors.

participants and study overview: in this randomised placebo-controlled trial, the investigators will include 30 pd patients with hy\>2 and l-dopa unresponsive gait characteristics. each participant will complete 1 visit, during which the instrumented stand and walk test will be repeated 16 times. the baseline measurement will be followed by three different stimulation conditions sham vns (svns), tavns at 25hz (tavns25) and tavns a 100hz (tavns100). svns, tavns25 and tavns100 in a randomized order. to enhance gait disturbances, the participants will perform isaw during each condition twice in silence and twice while simultaneously performing calculations around. instrumented stand and walk test (isaw): to perform isaw, participants will first stand still for 30s, after which they will start walking in a straight line for 7m, turn and walk back to the start. the participants will be equipped with 6 inertion opal ® motion sensors (on both feet, both wrists, on the lumbar back and on their sternum). for the laud counting isaw condition (isaw-c), the participants will perform isaw as described above while also counting backwards by 3 from numbers above 100. tavns: noninvasive electrostimulation will be applied to the left ear. tavns will be applied to the cyma conchae and svns will be applied to the earlobe. both tavns and svns were applied through the nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1ma above the perceptual threshold (figure 1). tavns25 and svns will be applied at 25hz and tavns100 will be applied at 100hz. the intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment. for each condition, the electrode will be placed in the ear by a third person and the ear will be covered by cotton pads and an eeg cap to hide the electrode position from the experimenter. the order of stimulation will not be revealed until the automated data and statistical analysis.

Eligibility criteria:
inclusion criteria: * hystage \>2 * l-dopa unresponsive gait characteristics present, preferably with history of freezings exclusion criteria: * unable to walk for 50m * unable to follow simple commands due to hearing loss/cognitive impairment

Keywords: parkinson's disease tavns motion sensors
sleep quality in carpal tunnel syndrome, splinting and kinesiotaping

Conditions: Carpal Tunnel Syndrome

Summary: the effect of conservative treatments on sleep quality in carpal tunnel syndrome is unclear. comparing the effect of splinting and kinesiotaping in carpal tunnel syndrome on functional status, pain, grip strength, nerve cross-sectional area and sleep quality. participants were divided into 3 groups. one group received night splint and nerve tendon gliding exercises, one group received kinesiotaping and nerve tendon gliding exercises, and one group received only nerve tendon gliding exercises. participants were evaluated by a blinded investigator at baseline and at 3 months by visual analogue scale (vas), boston carpal tunnel syndrome questionnaire, pittsburgh sleep quality index (psqi), jamar hand dynamometer and ultrasonography.


Eligibility criteria:
inclusion criteria * being diagnosed with mild and moderate carpal tunnel syndrome with nerve conduction velocity study * to be between the ages of 18-65 exclusion criteria: * inflammatory disease (rheumatoid arthritis, tendinitis, etc.), * osteoarthritis in the hand/wrist, * musculoskeletal conditions (hand, elbow, wrist), * thyroid disease * chronic kidney failure * carpal tunnel syndrome surgery, * history of surgery and/or trauma to the upper extremity and neck. * pregnancy or diabetes-related carpal tunnel syndrome, * receiving any treatment for carpal tunnel syndrome (splint therapy, electrophysical agents, exercise, local corticosteroid injection) up to 3 months prior to the tests.
actengine® ima203 combined with mrna-4203

Conditions: Cutaneous Melanoma; Synovial Sarcoma

Summary: this purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of ima203 in combination with different doses of mrna-4203. the trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (cm) or synovial sarcoma (ss).

this clinical trial is a multi-center, open-label, non-comparative phase 1 a/b trial to assess the safety, tolerability, and anti-tumor activity of the combination of ima203 and mrna-4203 in hla-a\*02:01 positive patients with previously treated, unresectable or metastatic cutaneous melanoma (cm) and synovial sarcoma (ss).

Eligibility criteria:
inclusion criteria: * pathologically confirmed and documented cutaneous melanoma (cm) or synovial sarcoma (ss) with unresectable or metastatic disease * hla-a\*02:01 positive * adequate selected organ function per protocol * eastern cooperative oncology group (ecog) performance status 0-1 * measurable disease according to response evaluation criteria in solid tumors (recist 1.1) * life expectancy more than 5 months * cm participants who must have disease progression (resistance, toxicity) on or after at least one pd-1 inhibitor * ss participants must have received (or declined) at least one line of treatment (including soc) and are still in need of further systemic therapy. * female participants of childbearing potential must use adequate contraception prior to trial entry until 12 months after the infusion of ima203 and 15 days after the last mrna 4203 dose administration other protocol defined inclusion criteria could apply exclusion criteria: * history of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years * pregnant or breastfeeding * serious autoimmune disease * history of cardiac conditions as per protocol * prior allogenic stem cell transplantation or solid organ transplantation * concurrent severe and/or uncontrolled medical disease that could compromise participation in the study * history of hypersensitivity to cyclophosphamide, fludarabine, or il-2 * history of hypersensitivity to mrna-based medicines * positive for hiv infection or with active hepatitis b virus (hbv) or active hepatitis c virus (hcv) infection * any condition contraindicating leukapheresis * participants with lactate dehydrogenase (ldh) greater than threshold allowed per protocol * participants with active brain metastases prior to lymphodepletion * concurrent treatment in another clinical trial or a device trial that could interfere with the ima203 treatment * participants with renal impairment and reduced bone marrow reserve per protocol other protocol defined exclusion criteria could apply

Keywords: immunotherapy t-cell therapy cutaneous melanoma synovial sarcoma rna vaccine immatics moderna
exploratory study of the effects of vortioxetine (lu aa21004) on cognition and blood oxygen level dependent (bold) functional magnetic resonance imaging (fmri) signals in subjects remitted from depression and in controls

Conditions: Depression

Summary: the purpose of this study is to determine if vortioxetine 20 mg/day will lead to changes in neural activity (bold signal), as measured using fmri, in brain areas associated with executive functioning and memory during cognitive task performances compared to placebo in subjects remitted from depression and in controls, and to explore if vortioxetine will lead to improved cognitive performance in the absence of depression.


Eligibility criteria:
inclusion criteria: all subjects must have: * a hamilton depression rating scale (ham-d17) total score ≤ 7 subjects remitted from depression must: * be in remission from recurrent depression having suffered from at least two previous major depressive episodes (mdes) * have received prescribed treatment with an antidepressant or a recognised psychotherapy for depression for a previous mde * report present subjective cognitive dysfunction * not have been treated with antidepressants or received other psychotherapy for depression for at least six weeks prior to screening visit control group subjects must: * have no history of mdes * have no history of mdes in a biological parent or other first degree relative as reported by the subject * not report present subjective cognitive dysfunction * never have been treated with antidepressants or psychotherapy exclusion criteria: * the subject is, in the opinion of the investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason other inclusion and exclusion criteria may apply.
ebus-miniforceps biopsy specimen acquisition for pd-l1 testing in nonsmall cell lung cancer

Conditions: Non Small Cell Lung Cancer; NSCLC

Summary: the incorporation of pd-l1 testing into clinical practice has progressed at a rapid pace, and now offers an additional line of therapy for eligible patients with nonsmall cell lung cancer. the assay used to detect circulating levels of pd-l1 currently requires core biopsies, and is not approved to be used for specimens collected through a needle based cytological technique. though endobronchial ultrasound guided transbronchial needle aspiration (ebus-tbna) has markedly improved the manner in which patients are diagnosed and staged for lung cancer, alternative means of tissue collection may be mandatory to offer patients access to newer lines of therapy such as pd-l1 inhibition. ebus-miniforceps biopsy may allow bronchoscopists to obtain core biopsy specimens through the technique of endobronchial ultrasound, so that more invasive approaches such as surgery may be avoided. feasibility using this approach would indicate that all patients being staged with endobronchial ultrasound procedures would be candidates for pd-l1 testing and potential therapy. this study is proposed to evaluate the feasibility of using endobronchial ultrasound guided miniforceps biopsy (ebus-mfb) to acquire tissue that is adequate for pd-l1 testing. feasibility in this study is defined as the ability to obtain adequate material during ebus procedures to perform pd-l1 testing.


Eligibility criteria:
inclusion criteria: * patients with central lung lesion 1cm in size or larger identified on chest ct with the intention to undergo bronchoscopic evaluation and biopsy. the decision to pursue biopsy will be made by the treating physician and agreed upon by the patient. * are at least 18 years old * are able to provide informed consent * are not pregnant as confirmed by bhcg testing prior to procedure exclusion criteria: * patients who refuse to participate * are less than 18 years of age * are pregnant * are physically unable to tolerate flexible bronchoscopy or moderate sedation as determined by the bronchoscopist * are unable to provide informed consent * are on anticoagulant medications and who cannot safely discontinue their medication prior to their procedure at the recommendation of their treating physician
cardiac monitor employee study

Conditions: Arrhythmias, Cardiac

Summary: this purpose of this study is to collect ecg data from a wearable cardiac monitor in order to evaluate end-to-end performance of a cardiac monitor system and associated data management accessories.

the objective of this study is to evaluate the usability of the wearable cardiac monitor (wcm) system including the wcm, mobile monitors (patient and clinician), magnet and latitude clarity(tm) server. the study will exercise the end-to-end system utilizing human ecg data generated by the wearable cardiac monitor.

Eligibility criteria:
inclusion criteria: * willing and capable to provide informed consent * age 18 or above * employee of the study sponsor * willing and able to follow protocol requirements exclusion criteria: * currently enrolled in another clinical study that interferes with data collection * currently implanted with an active medical electronic device * known allergies to the materials that may come in contact with the skin * any active skin condition on the chest reported by the subject
a phase 2 trial testing zp1848 in patients with sbs

Conditions: Short Bowel Syndrome

Summary: a proof-of-concept, dose finding, controlled, single-center, randomized, double-blind, fixed dose phase 2 trial with zp1848 in patients with short bowel syndrome.


Eligibility criteria:
inclusion criteria: * following receipt of verbal and written information about the trial, the patient must provide signed informed consent before any trial related activity is carried out. * age ≥ 18 years and ≤ 90 years * stable sbs patients with intestinal insufficiency or failure, where the last surgical resection of gut tissue was performed at least 1 year ago * a stable ps volume ( \< 25% change in volume or energy content) for four weeks prior to randomization for patients requiring ps * wet weight of fecal excretion ≥ 1500 g/day demonstrated during a hospital stay prior to screening or during at least one day of the first baseline balance study. * stable body weight (\<5% weight deviance in the three months prior to screening) exclusion criteria: * patients with known or suspected intestinal strictures of clinical relevance as judged by the investigator * active inflammatory bowel disease (ibd) or fistula during the screening period as judged by conventional means of the investigator. * crohn's disease patients not being in clinical remission for the last 12 weeks prior to randomization * cardiac disease defined as: decompensated heart failure (nyha class iii-iv) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months prior to screening * history of cancer (except resected cutaneous basal or squamous cell carcinoma and except in situ cervical cancer) unless it can be documented that the patient has been in a disease-free state for at least 5 years (except colon cancer: patients with a history of colon cancer generally have to be excluded) * egfr (by the mdrd formula) \<30 ml/min/1.73 m2 * clinically meaningful renal disease as judged by the investigator
exploratory study evaluating the effects of darifenacin on nocturia, sleep and daytime wakefulness

Conditions: Nocturia

Summary: the purpose of this study is to evaluate the efficacy of darifenacin in the treatment of moderate to severe nocturia in patients with overactive bladder and who do not have non-urologic causes of nocturia.


Eligibility criteria:
inclusion criteria: * subject must be aged 21-70, inclusive. * subject mush have given written, personally signed and dated informed consent. * subject must be diagnosed with overactive bladder. * subject must have a nocturia frequency of greater than or equal to 3 episodes a night. * subject must be male or non-pregnant, non-lactating female who agrees to comply with applicable contraceptive requirements. * subject understands and is able, will a nd and likely to fully comply with study procedures and restrictions. exclusion criteria: * subject has any concurrent chronic or acute illness or unstable medical condition either treated or untreated that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol. * the subject has a known or suspected allergy, hypersensitivity, or other medical contraindications to darifenacin (enablex®) (or its components). * the subject has concomitant diseases in which the use of anticholinergic drugs is contraindicated, e.g. urinary retention, bladder obstruction, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe hepatic impairment (child pugh c), severe ulcerative colitis, toxic megacolon, and patients who are at risk for these conditions. * subject is taking another drug which is considered to have significant anticholinergic activity. * use of drugs known to effect cognition, alertness or drowsiness, such as benzodiazepines, sedating antihistamines, opioids, or other sedative hypnotic drugs. * subject has moderate to severe obstructive sleep apnea (apnea/hypopnea index ≥ 15) * subject has a medical condition other than oab that is the most likely cause of the subject's nocturia (e.g., primary sleep disorder, polydipsia, polyuria). * subject has taken another investigational drug or taken part in a clinical trial within the last 30 days prior to screening. * the female subject is pregnant or lactating. * subjects with a urine drug screen positive for stimulants, barbiturates, hallucinogens, opiates, cocaine, cannabis, or amphetamines
effect of mosapride citrate on gastrointestinal motility after laparoscopic gastrectomy

Conditions: Stomach Cancer

Summary: "mosapride citrate is a 5-hydroxytryptamine 4 receptor agonist, and is widely used as an agent to increase intestinal motility. mosapride citrate has been demonstrated in in vitro and in vivo studies to increase both gastric and colon motility. in a case-control study of patients undergoing colonectomy, mosapride citrate was found to significantly reduce gas passing and defecation time. recently, a study reported that mosapride citrate acts on the α7nach receptor and, consequently, suppresses the inflammatory response of macrophages, thereby suppressing the mechanism that induces paralysis after surgery. to date, this study is intended to analyze whether mosapride citrate significantly affects the improvement of bowel movement after surgery after gastrectomy."


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with gastric cancer pathologically before surgery 2. patients who underwent surgical resection (r0 resection) 3. patients with an asa score of 3 or less exclusion criteria: 1. patients over 80 years old 2. when there are multiple or peritoneal metastases 3. intestinal obstruction before surgery 4. when chemotherapy was performed before surgery 5. when cancer other than stomach cancer is diagnosed 6. if you have a long history of major intra-abdominal surgery or a history of abdominal radiotherapy 7. in case of liver failure or kidney failure 8. when it is judged that uncontrolled diabetes may affect intestinal function

Keywords: gastrectomy, intestinal motility, mosapride, adhesion, ileus
study to determine the accuracy of prothrombin time of warfarinised blood

Conditions: Clotting Disorders

Summary: the purpose of this study is to measure prothrombin time (pt) expressed in international normalised ratio (inr) units in persons receiving coumadin (warfarin) treatment on an experimental device and a commercially available device. this study will involve taking a finger-puncture and testing onto a strip and meter system for the experimental and commercially available devices.


Eligibility criteria:
inclusion criteria: * are currently taking coumadin (warfarin) * are aged 18 years or older * able and willing to provide informed consent * can understand (read and write) english * required to provide a capillary sample as part of their routine medical check exclusion criteria: * previously participated in this study
clusterin level and polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Ovulation Disorder

Summary: clusterin, a protein involved in metabolic syndrome, insulin resistance, and metabolic disorders associated with inflammation and oxidative stress such as atherosclerosis, alzheimer's and some malignancies, has elevated levels in metabolic syndrome, pcos, and the combination of these two groups. clusterin could be used as an inflammatory marker to predict pcos and metabolic syndrome.

the study included 118 women diagnosed with pcos according to the rotterdam criteria and 62 age-matched healthy women without cardiovascular risk factors. the patients diagnosed with pcos were also classified into phenotypes. no interventional examination was requested for patients a, b, c, and d, except for hormonal tests and blood collection for human clusterin. the demographic and clinical characteristics of all patients were compared, with the primary outcome being blood clusterin levels. the secondary outcomes are blood clusterin levels in women with and without metabolic syndrome in addition to pcos, the relationship between pcos phenotypes and clusterin levels, and the relationship between clusterin levels and clinical and laboratory parameters.

Eligibility criteria:
inclusion criteria: * women aged between 18 and 45, * natural bilateral ovaries and no functional cysts on transvaginal ultrasound. exclusion criteria: * who have hyperandrogenism/hyperandrogenemia * who have non-classical congenital adrenal hyperplasia (17 ohp value \>2 nmol/l) * who have thyroid disease (tsh \>5 mlu/l), * women with hyperprolactinemia (prolactin\>30 mlu/ml) * patients taking hormonal drugs or ovulation induction agents.

Keywords: clusterin metabolic syndrome